Extrait

Primary objective - To evaluate the quality of life of Adalimumab treated patients over a period of 12 months Secondary objectives - To evaluate the long-term efficacy of Adalimumab in patients with moderate to severe chronic plaque psoriasis as prescribed by the dermatologists in day-to-day clinical practice and in accordance with the terms of the European marketing authorization. - To evaluate changes in patients quality of life according to treatment response over a 12-month period - To observe and assess the long term use and safety of Adalimumab as prescribed by the dermatologist in a normal clinical setting and in accordance with the terms of the European marketing authorization.

Critère d'inclusion

• Psoriasis

Liens

• nct
• ictrp